KCNQ2 Antibodies

Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2)

Associates with KCNQ3 to form a potassium channel with basically identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in setting the subthreshold electrical excitability of neurons in addition to the responsiveness to synaptic inputs. Therefore, it's important in the regulation of neuronal excitability.

KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and triggered by the anticonvulsant retigabine (PubMed:9836639, PubMed:11572947, PubMed:14534157, PubMed:12742592, PubMed:17872363). As the native M-channel, the potassium channel composed of KCNQ2 and KCNQ3 can also be suppressed by activation of the muscarinic acetylcholine receptor CHRM1 (PubMed:10684873).

Gene Information

Human
Gene Name:	KCNQ2
Uniprot:	O43526
Entrez:	3785

Family

Belongs to:
potassium channel family

Alternative Names

BFNC; BFNS1; EBN; EBN1; EIEE7; ENB1; HNSPC; KCNA11; KQT-like 2; Kv7.2; KVEBN1; neuroblastoma-specific potassium channel protein; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; potassium voltage-gated channel subfamily KQT member 2; potassium voltage-gated channel, KQT-like subfamily, member 2; Voltage-gated potassium channel subunit Kv7.2

Molecular Weight

Mass (kDA):
95.848 kDA

Genomic Context

Human
Location:	20q13.33
Sequence:	20; NC_000020.11 (63400208..63472655, complement)

Tissue Specificity

In adult and fetal brain. Highly expressed in areas containing neuronal cell bodies, low in spinal chord and corpus callosum. Isoform 2 is preferentially expressed in differentiated neurons. Isoform 6 is prominent in fetal brain, undifferentiated neuroblastoma cells and brain tumors.

Subcellular Localizations

Cell membrane; Multi-pass membrane protein.

Diseases

• Epilepsy
• Convulsion Neonatal
• Familial Benign Neonatal Epilepsy
• Convulsions
• Benign Neonatal Epilepsy
• Epilepsy, Generalized
• Pain
• Nervousness
• Febrile Convulsions
• Myokymia
• Channelopathies
• Epilepsies, Myoclonic

• Neuralgia
• Autosomal Dominant Form Of Benign Neonatal Seizures
• Long Qt Syndrome
• Epilepsy, Frontal Lobe
• Epilepsies, Partial
• Tonic-clonic Epilepsy

Pathways

• Pathogenesis
• Localization
• Membrane Depolarization
• Transport
• Cognition
• Hypersensitivity
• Exocytosis
• Brain Development
• Sensitization
• Glycosylation
• Lipid Phosphorylation
• Protein Phosphorylation
• Muscle Contraction

• Neurogenesis
• Transepithelial Transport
• Protein Glycosylation
• Swimming
• Reverse Transcription
• Translation
• Gliogenesis

PTMs

• Phosphorylation
• Reduction
• Glycosylation
• Cleavage

• Ubiquitination
• Biotinylation
• Dephosphorylation
• Ribosylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KCNQ2

Best Uses Of The KCNQ2 Marker

Steven Boster has been researching antibodies since 1993. His first product, Boster Bio, earned him the nickname "he who converts science in the lavatory." He later developed various products for immunohistochemistry (IHC) and developed hundreds of primary antibodies. Boster Bio was quickly established as the largest Chinese catalog antibody company in the late 1990s. PicoKine(tm), a proprietary ELISA technology developed by Boster Bio delivers high-sensitivity ELISA Kits.

Steven Boster's primary antibodies are trusted by the research community

Before the primary antibody used for research can be published, it needs to be validated. It should also be made publicly available with sequences cited and included within methods descriptions. Users must follow the protocols and trust antibody suppliers. Scientists should not rely on large aggregators of unpublished antibody, but monoclonal antibodies. Journals should require precise citations. Data and citations must be disseminated from independent internet sources. Young investigators should be trained by research funding agencies to use antibodies in their studies.

Researchers who use Boster's antibody products are confident in their quality and consistency. Boster antibodies have been proven to be reliable and highly effective by researchers for more than 25 years. They have also been thoroughly tested in immunohistochemistry and Western Blotting. Boster antibodies are compatible also with other brands, such as ELISA kits and primary antibodies. Scientists should trust primary antibodies from Boster for all these reasons.

Commercially produced antibodies are widely criticized for their poor characterization, which can lead to irreproducible experimental results. Commercial antibodies may not be suitable for the type and subject matter of your experiment. These problems were addressed by speakers from the commercial, academic, and non-profit sectors. GBSI and Antibody Society are currently working together on a taskforce to establish a set standards for antibodies.

Steven Boster's history

Steve Boster was the inventor of his first product. In 1993, he earned the nickname "he converts science in a lavatory". He would later develop hundreds of primary antibody products for various medical applications. In the late 90s, he was leading China's largest catalogue antibody company. PicoKine(tm), a proprietary ELISA platform, was created by him. He is now a major provider of high-sensitivity ELISA Kits thanks to his proprietary trade secrets.

Steve Boster died on June 26, 2022. He was born in Joliet (IL) and died in Madison, WI. He was the father, Sr., David Boster, Nina Mae Hall. Frances, his daughter Crystal and Natosha were his parents. He also leaves behind 4 brothers, Jack Boster (Sandra Blanton) and sister Lisa Milton.